J Mervyn Nabors Net Worth

The estimated Net Worth of J Mervyn Nabors is at least 7.71 百万$ dollars as of 3 June 2004. J Nabors owns over 1,096,572 units of AIM ImmunoTech Inc stock worth over 3,800$ and over the last 20 years J sold AIM stock worth over 7,708,901$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

J Nabors AIM stock SEC Form 4 insiders trading

J has made over 1 trades of the AIM ImmunoTech Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently J sold 1,096,572 units of AIM stock worth 7,708,901$ on 3 June 2004.

The largest trade J's ever made was selling 1,096,572 units of AIM ImmunoTech Inc stock on 3 June 2004 worth over 7,708,901$. On average, J trades about 1,096,572 units every 0 days since 2004. As of 3 June 2004 J still owns at least 12,262 units of AIM ImmunoTech Inc stock.

You can see the complete history of J Nabors stock trades at the bottom of the page.

What's J Nabors's mailing address?

J's mailing address filed with the SEC is 271 BAYSIDE DR, , CLEARWATER BEACH, FL, 34630.

Insiders trading at AIM ImmunoTech Inc

Over the last 20 years, insiders at AIM ImmunoTech Inc have traded over 15,026,013$ worth of AIM ImmunoTech Inc stock and bought 898,126 units worth 656,210$ . The most active insiders traders include Thomas K Equels、J Mervyn Nabors、Commercial Bank First. On average, AIM ImmunoTech Inc executives and independent directors trade stock every 125 days with the average trade being worth of 16,943$. The most recent stock trade was executed by Thomas K Equels on 6 May 2024, trading 61,729 units of AIM stock currently worth 25,309$.

What does AIM ImmunoTech Inc do?

aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as

Complete history of J Nabors stock trades at AIM ImmunoTech Inc

AIM ImmunoTech Inc executives and stock owners

AIM ImmunoTech Inc executives and other stock owners filed with the SEC include:

• William Mitchell,
  Chairman of the Board
• Thomas K. Equels Esq., J.D., M.S.,
  Exec. Vice Chairman, CEO & Pres
• Thomas Equels,
  Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel
• Thomas K. Equels,
  Exec. Vice Chairman, CEO & Pres
• Peter W. Rodino III, Esq., J.D.,
  COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec.
• Wayne Springate,
  Senior Vice President - Operations
• David Strayer,
  Chief Scientific & Medical Officer
• Ellen M. Lintal,
  CFO & Chief Accounting Officer
• Charles Jones,
  Investor Relations
• Stewart Appelrouth,
  Director
• Peter Rodino,
  Chief Operating Officer, General Counsel, Secretary
• Ellen Lintal,
  Chief Financial Officer
• Jodie Pelz,
  Controller
• Dr. David R. Strayer M.D.,
  Chief Scientific Officer & Medical Director
• Robert Dickey IV, M.B.A.,
  Chief Financial Officer
• Dr. Ralph Christopher Cavalli Ph.D.,
  VP of QC & Manufacturing
• Dr. Ralph Christopher Cavalli,
  VP of QC & Manufacturing
• Julie Mierau,
  Controller
• Dr. Carol A. Smith,
  Chief Manufacturing Officer & Deputy Chief Scientific Officer
• Ann Marie E. Coverly,
  Director of Admin. & HR and Deputy Investor Relations Coordinator
• Dr. David R. Strayer,
  Chief Scientific Officer & Medical Director
• Roy Robinson,
  Director
• Douglas Hillman,
  President, CEO and Director
• Donald Russell,
  Director
• Thomas E Whytas,
  Director
• David M Vosen,
  Director
• Technik Industries, Inc. El...,
  10% owner
• Kevin J Purcell,
  EVP and Chief Financial Office
• Robert J Mcgill,
  Director
• Mark Perkins,
  Executive V.P.
• Thomas Wright Cason,
  Executive Vice President, COO
• Commercial Bank First,
  10% owner
• Carmelo Russo,
  Executive V.P.
• David A Baldini,
  President and CEO
• Gary E Colbert,
  Executive VP and CFO
• J Mervyn Nabors,
  10% owner
• Nancy Bryan,
  Director